Prion-Like Spreading in Neurodegenerative Diseases

Prion-Like Spreading in Neurodegenerative Diseases

Overview

Prion-like propagation represents one of the most transformative concepts in neurodegenerative disease research, explaining how protein pathology spreads throughout the brain in a predictable pattern. Originally discovered in prion diseases like Creutzfeldt-Jakob disease, the principle of template-guided protein misfolding and cell-to-cell transmission has now been extended to Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and frontotemporal dementia[@prionlike2021].

This mechanism explains the characteristic spreading patterns observed in postmortem brain tissue, where pathology advances along anatomically connected neural networks rather than appearing randomly throughout the brain. The recognition that multiple neurodegenerative diseases share this propagation mechanism has fundamentally changed our understanding of disease progression and opened new therapeutic avenues[@jucker2018].

Common Principles of Prion-Like Propagation

Template-Guided Misfolding

All prion-like proteins share the ability to convert normal, native proteins into their misfolded conformations through a process termed "templated nucleation"[@soto2011]. The misfolded protein serves as a template that catalyzes the conformational conversion of normal proteins:

Prion-Like Spreading in Neurodegenerative Diseases

Overview

Prion-like propagation represents one of the most transformative concepts in neurodegenerative disease research, explaining how protein pathology spreads throughout the brain in a predictable pattern. Originally discovered in prion diseases like Creutzfeldt-Jakob disease, the principle of template-guided protein misfolding and cell-to-cell transmission has now been extended to Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and frontotemporal dementia[@prionlike2021].

This mechanism explains the characteristic spreading patterns observed in postmortem brain tissue, where pathology advances along anatomically connected neural networks rather than appearing randomly throughout the brain. The recognition that multiple neurodegenerative diseases share this propagation mechanism has fundamentally changed our understanding of disease progression and opened new therapeutic avenues[@jucker2018].

Common Principles of Prion-Like Propagation

Template-Guided Misfolding

All prion-like proteins share the ability to convert normal, native proteins into their misfolded conformations through a process termed "templated nucleation"[@soto2011]. The misfolded protein serves as a template that catalyzes the conformational conversion of normal proteins:

This templated conversion distinguishes prion-like propagation from classical protein aggregation, as the presence of a seed dramatically accelerates the nucleation process and ensures strain-specific conformations are maintained during propagation[@walker2020].

Tau Oligomer Transmission

Tau oligomers represent the most toxic species in Alzheimer's disease and play a critical role in prion-like spreading[@lasagnareeves2012]. Unlike mature neurofibrillary tangles (NFTs), tau oligomers are soluble, prefibrillar aggregates that:

• Form transiently before maturing into PHFs
• Exhibit increased cytotoxicity compared to monomeric or fibrillar tau
• Transfer more efficiently between cells due to their smaller size
• Serve as primary seeding entities in template-guided misfolding

Seed Propagation Mechanisms

The propagation of pathological protein seeds occurs through multiple coordinated mechanisms:

Cellular Release Pathways:

• Synaptic activity-dependent release: Neuronal activity promotes the release of pathological proteins into the extracellular space[@pooler2013]
• Exosome secretion: Small extracellular vesicles carry protein seeds and can traverse biological barriers[@saman2012]
• Tunneling nanotube (TNT) formation: Direct cytoplasmic connections between cells enable direct transfer of oligomeric species[@abiega2016]
• Necrotic cell lysis: Cell death releases intracellular aggregates that can be taken up by neighboring cells

• Receptor-mediated endocytosis: Specific receptors facilitate selective uptake of pathological proteins
• Membrane fusion: Direct fusion with plasma membrane allows internalization
• Macropinocytosis: Bulk fluid-phase uptake contributes to non-selective internalization

Strain Diversity

Distinct conformational variants (strains) of the same protein can encode different disease phenotypes[@guo2013]. These strains represent alternative misfolded states that:

• Maintain their conformational properties during propagation across generations
• Produce distinct neuropathological patterns in recipient cells
• May explain phenotypic variability within the same disease category
• Demonstrate different seeding efficiencies and aggregation kinetics

Amyloid-Beta Propagation

Mechanism

[Amyloid-beta](/proteins/amyloid-beta) (Aβ) propagation in Alzheimer's disease follows the prion-like template mechanism, though with some unique features compared to other neurodegenerative proteins[@hamaguchi2016]. Aβ seeds can template the misfolding of endogenous Aβ, promoting plaque formation in previously unaffected brain regions.

Propagation Pathway

Braak Staging

While most commonly applied to tau pathology, Aβ plaque deposition follows a staging system:

• Stage I-II: Isocortex
• Stage III-IV: Allocortical structures (entorhinal cortex, hippocampus)
• Stage V-VI: Subcortical regions, brainstem

Evidence

The prion-like nature of Aβ is supported by:

• Experimental inoculation studies showing Aβ pathology induction in animal models[@kane2000]
• Presence of Aβ seeds in cerebrospinal fluid of AD patients
• Correlation between connectome-based spread and clinical progression
• Transmission of Aβ pathology in rare iatrogenic CJD cases with dural grafts[@jaunmuktane2015]

Tau Propagation

Mechanism

Tau propagation represents one of the best-characterized prion-like mechanisms in neurodegeneration[@mudher2017]. Hyperphosphorylated tau dissociates from microtubules, aggregates into paired helical filaments (PHFs), and spreads through interconnected brain regions.

Propagation Pathway

Braak Staging

Tau neurofibrillary tangles follow a highly predictable spreading pattern:

• Braak I: Transentorhinal cortex (clinically silent)
• Braak II: Entorhinal cortex
• Braak III: Hippocampus (early MCI)
• Braak IV: Limbic structures
• Braak V: Association neocortex (moderate dementia)
• Braak VI: Primary motor/sensory cortex (severe dementia)

Cell-to-Cell Transfer

Tau spreads through multiple mechanisms:

| Mechanism | Description | Evidence |
|-----------|-------------|----------|
| Synaptic activity | Tau is released from presynaptic terminals during neuronal activity | In vitro studies show activity-dependent release[@yamada2014] |
| Extracellular vesicles | Exosomal tau transport between cells | Exosomal tau detected in CSF and media[@wang2017] |
| Tunneling nanotubes | Direct intercellular transfer via TNTs | Transfer observed in co-culture systems[@tardivel2016] |
| Non-synaptic release | Activity-dependent release independent of synapses | Microdialysis studies in human brain[@bancher2016] |

Therapeutic Targeting of Tau Propagation

Understanding tau propagation has enabled development of novel therapeutic strategies:

Alpha-Synuclein Propagation

Mechanism

Alpha-synuclein (α-syn) propagation underlies Parkinson's disease progression and defines the synucleinopathies including PD, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)[@bridi2018]. Unlike tau and Aβ, α-syn propagation involves both inside-out and outside-in mechanisms.

Propagation Pathway

Braak Staging

α-syn pathology follows a bottom-up progression:

• Stage 1: Dorsal motor nucleus of vagus, enteric nervous system
• Stage 2: Locus coeruleus, raphe nuclei
• Stage 3: Substantia nigra pars compacta
• Stage 4: Temporal mesocortex, allocortex
• Stage 5-6: Neocortex

MSA vs. PD

A critical distinction exists in α-syn strains between:

• PD/DLB: Neuronal α-syn pathology (Lewy bodies)
• MSA: Oligodendroglial α-syn pathology (Glial cytoplasmic inclusions)

TDP-43 Propagation

Mechanism

TDP-43 propagation occurs in ALS and most cases of frontotemporal dementia[@rascovsky2020]. Unlike the extracellular proteins above, TDP-43 propagation is primarily a neuronal phenomenon with cytoplasmic mislocalization rather than extracellular transmission.

Propagation Pathway

Propagation Pattern

TDP-43 pathology spreads:

• From spinal cord motor neurons to cortex
• Along corticospinal tracts
• Into frontal and temporal cortices
• Following a hierarchical vulnerability pattern

Unique Features

• No extracellular phase: TDP-43 remains intracellular throughout propagation
• RNA-binding function: Loss of nuclear function contributes to toxicity
• Stress granule association: Dynamic liquid-liquid phase separation modulates aggregation[@armakola2012]

Huntingtin Propagation

Mechanism

Huntingtin (HTT) aggregation in Huntington's disease involves polyglutamine (polyQ) expansion, creating a distinct prion-like mechanism[@tattersfield2014]. While classical prion-like spreading is less established, evidence suggests template-assisted propagation.

Propagation Pathway

Pattern

[Huntingtin](/proteins/huntingtin) pathology:

• Begins in striatum and [cortex](/brain-regions/cortex)
• Spreads to thalamus, hypothalamus
• Eventually affects most brain regions
• Follows regional vulnerability rather than network spread

Evidence for Prion-Like Behavior

• Mutant HTT can induce misfolding of wild-type HTT in cellular models[@ren2019]
• Inoculation studies show template-dependent aggregation
• Exosomal mutant HTT detected in patient biofluids

Comparative Analysis

Summary Table

| Protein | Primary Disease | Braak-like Staging | Extracellular | Key Mechanism |
|---------|----------------|-------------------|---------------|---------------|
| Aβ | Alzheimer's | Yes (stages I-VI) | Yes | Plaque spreading |
| Tau | AD/FTD | Yes (stages I-VI) | Yes | Network-based |
| α-syn | PD/DLB/MSA | Yes (stages 1-6) | Yes | Synaptic transmission |
| TDP-43 | ALS/FTD | Yes | No | Corticospinal tract |
| HTT | Huntington's | No | Limited | Regional vulnerability |

Therapeutic Implications

Understanding prion-like propagation has led to therapeutic strategies:

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Huntington's Disease](/diseases/huntington-disease)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Alpha-Synuclein Protein](/proteins/alpha-synuclein)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Protein Aggregation Comparison](/mechanisms/protein-aggregation-comparison)

Molecular Mechanisms of Templated Misfolding

Nucleation-Dependent Aggregation

The nucleation-dependent aggregation model provides the framework for understanding prion-like propagation[@prionlike2021]. This process involves:

Primary Nucleation:

• Spontaneous formation of misfolded oligomers from native proteins
• Represents the rate-limiting step in aggregation
• Requires overcoming a thermodynamic barrier
• Can be accelerated by mutations or post-translational modifications

• Seed-induced formation of new aggregates
• Much faster than primary nucleation
• Forms the basis for exponential propagation
• Template preserves strain-specific conformation during amplification

• Aggregation occurs on existing fibril surfaces
• Explains the accelerating nature of pathology spread
• Particularly relevant at late disease stages

Conformational Strain Encoding

The information content of prion-like strains resides in the three-dimensional structure of the aggregated protein[@jucker2018]. This structural encoding:

• Determines the biological properties of the aggregate
• Is maintained through templated conversion
• Can evolve during propagation (strain mutation)
• Influences cellular vulnerability and disease phenotype

Intercellular Spread Mechanisms in Detail

Tunneling Nanotubes

Tunneling nanotubes (TNTs) represent a direct cell-to-cell communication channel that enables transfer of various cargoes including pathological proteins[@walker2020]. Key characteristics:

• Formed by actin-driven membrane protrusion
• Can span up to 100 μm between cells
• Enable bidirectional transfer of proteins, organelles, and RNA
• Display selective cargo preference based on protein properties
• Upregulated under cellular stress conditions

Extracellular Vesicles

Extracellular vesicles (EVs) including exosomes and microvesicles serve as important vehicles for pathological protein spread[@lasagnareeves2012]:

| Vesicle Type | Size | Biogenesis | Cargo |
|---------------|------|------------|-------|
| Exosomes | 30-150 nm | Endosomal pathway | α-syn, tau, Aβ |
| Microvesicles | 100-1000 nm | Plasma membrane shedding | TDP-43, HTT |
| Apoptotic bodies | 1000-5000 nm | Apoptosis | All proteins |

Synaptic Transmission

Synaptic activity plays a dual role in prion-like propagation:

• Activity-dependent exocytosis
• Vesicular release at presynaptic terminals
• Postsynaptic receptor internalization and recycling

• Presynaptic terminal uptake
• Dendritic spine internalization
• Receptor-mediated endocytosis at synapses

Therapeutic Strategies Targeting Propagation

Immunotherapeutic Approaches

Active and passive immunization strategies aim to neutralize extracellular pathological proteins:

Passive Immunotherapy:

• Monoclonal antibodies against Aβ, tau, α-syn
• Intravenous immunoglobulin (IVIG) containing natural antibodies
• Antibody fragments and bispecific antibodies
• Engineered antibodies with enhanced brain penetration

• Aβ vaccination (e.g., ACC-001, CAD106)
• Tau vaccination approaches
• α-syn vaccination programs

Small Molecule Inhibitors

Targeted small molecules aim to:

• Inhibit primary and secondary nucleation
• Stabilize native protein conformation
• Block protein-protein interactions essential for aggregation
• Prevent cellular uptake of pathological seeds

Gene Therapy Approaches

Gene therapy offers potential for:

• Reducing expression of aggregation-prone proteins
• Enhancing autophagy and protein clearance pathways
• Delivering protective genetic variants
• Modifying receptors involved in protein uptake

Future Directions

The field of prion-like propagation continues to evolve with several key research areas:

See Also

• [Amyloid-beta](/proteins/amyloid-beta)
• [Huntingtin](/proteins/huntingtin)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Alpha-Synuclein Protein](/proteins/alpha-synuclein)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Protein Aggregation Comparison](/mechanisms/protein-aggregation-comparison)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References